How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics

Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B.In this episode, we discuss: • Why Gilgamesh is building psychedelic medicines the way large pharma would • The thesis behind short-acting psychedelics and why long-duration trips are impractical for real-world psychiatry • How Gilgamesh designs molecules backwards from clinical needs • Effective approaches to the challenges of trial designs for psychedelics  • What AbbVie’s deal and Spravato’s trajectory mean for psychedelics • How psychedelic medicines could reshape mental healthCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias and GregProduced by Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank